Vaccines News  |  view more news

07 August 2008

Novartis begins shipment to US of Fluvirin® Influenza Virus Vaccine with three new strains for the 2008-2009 influenza season

20 June 2008

Novartis Vaccines breaks ground for new rabies and TBE vaccine production facility in Marburg, Germany

04 June 2008

Novartis presents full pipeline of novel vaccines addressing significant unmet needs

14 May 2008

In a Phase II study, Novartis Meningitis B vaccine has potential to produce a protective immune response in infants[1], the age group most at risk

06 May 2008

Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial

Features

Invasive meningococcal disease
According to the World Health Organization, N. meningitidis causes about 500,000 cases of disease and 50,000 deaths worldwide annually. Infants and adolescents have the highest rate of disease, with the highest attack rates in infants three to 12 months old.

Flu Cell Culture Technology
Cell culture-derived influenza vaccine technology (“flu cell culture”) is an innovative production process for the manufacturing of flu vaccine on the basis of cell cultures.

Avian Influenza
The most recent avian influenza concerns first arose in 1997, when the H5N1 avian influenza virus first moved into humans.